OMEGA THERAPEUTICS INC (OMGA) Fundamental Analysis & Valuation

NASDAQ:OMGAUS68217N1054

Current stock price

0.1426 USD
-0.02 (-10.82%)
At close:
0.11 USD
-0.03 (-22.86%)
After Hours:

This OMGA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OMGA Profitability Analysis

1.1 Basic Checks

  • In the past year OMGA has reported negative net income.
  • In the past year OMGA has reported a negative cash flow from operations.
  • OMGA had negative earnings in each of the past 5 years.
  • In the past 5 years OMGA always reported negative operating cash flow.
OMGA Yearly Net Income VS EBIT VS OCF VS FCFOMGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • OMGA has a Return On Assets of -47.86%. This is comparable to the rest of the industry: OMGA outperforms 48.17% of its industry peers.
  • Looking at the Return On Equity, with a value of -633.21%, OMGA is doing worse than 80.98% of the companies in the same industry.
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROIC N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMGA Yearly ROA, ROE, ROICOMGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

  • OMGA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMGA Yearly Profit, Operating, Gross MarginsOMGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K -4K

1

2. OMGA Health Analysis

2.1 Basic Checks

  • OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OMGA has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for OMGA has been reduced compared to a year ago.
OMGA Yearly Shares OutstandingOMGA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OMGA Yearly Total Debt VS Total AssetsOMGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

  • OMGA has an Altman-Z score of -4.95. This is a bad value and indicates that OMGA is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of OMGA (-4.95) is worse than 60.73% of its industry peers.
  • OMGA has a Debt/Equity ratio of 1.00. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 1.00, OMGA is doing worse than 78.53% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -4.95
ROIC/WACCN/A
WACC9.59%
OMGA Yearly LT Debt VS Equity VS FCFOMGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
  • OMGA's Current ratio of 1.61 is on the low side compared to the rest of the industry. OMGA is outperformed by 80.80% of its industry peers.
  • A Quick Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
  • The Quick ratio of OMGA (1.61) is worse than 79.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
OMGA Yearly Current Assets VS Current LiabilitesOMGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

5

3. OMGA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.06% over the past year.
  • The Revenue has grown by 184.04% in the past year. This is a very strong growth!
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%

3.2 Future

  • Based on estimates for the next years, OMGA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.60% on average per year.
  • The Revenue is expected to grow by 150.92% on average over the next years. This is a very strong growth
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%

3.3 Evolution

OMGA Yearly Revenue VS EstimatesOMGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
OMGA Yearly EPS VS EstimatesOMGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

1

4. OMGA Valuation Analysis

4.1 Price/Earnings Ratio

  • OMGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMGA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMGA Price Earnings VS Forward Price EarningsOMGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMGA Per share dataOMGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OMGA's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%

0

5. OMGA Dividend Analysis

5.1 Amount

  • No dividends for OMGA!.
Industry RankSector Rank
Dividend Yield N/A

OMGA Fundamentals: All Metrics, Ratios and Statistics

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (2/24/2025, 8:00:02 PM)

After market: 0.11 -0.03 (-22.86%)

0.1426

-0.02 (-10.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06
Earnings (Next)N/A
Inst Owners81.36%
Inst Owner Change0%
Ins Owners1.4%
Ins Owner Change0%
Market Cap7.90M
Revenue(TTM)8.10M
Net Income(TTM)-73.09M
Analysts82.86
Price Target13.26 (9198.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.54%
PT rev (3m)40.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.3%
Cap/Sales 25.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -4.95
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A

OMEGA THERAPEUTICS INC / OMGA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of OMEGA THERAPEUTICS INC (OMGA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to OMGA.


What is the valuation status for OMGA stock?

ChartMill assigns a valuation rating of 1 / 10 to OMEGA THERAPEUTICS INC (OMGA). This can be considered as Overvalued.


What is the profitability of OMGA stock?

OMEGA THERAPEUTICS INC (OMGA) has a profitability rating of 0 / 10.


Can you provide the financial health for OMGA stock?

The financial health rating of OMEGA THERAPEUTICS INC (OMGA) is 1 / 10.


Can you provide the expected EPS growth for OMGA stock?

The Earnings per Share (EPS) of OMEGA THERAPEUTICS INC (OMGA) is expected to grow by 34.35% in the next year.